Peer-reviewed Neurology Publication on Medibio Science Medibio announces that a clinical article by Defillo et al. titled “Physiological Differences between Mood Disorder Phenotypes Based on Heart Rate Variability” has been published in EC Neurology, an internationally peer-reviewed journal. [...]

Sydney, Australia and Minneapolis, MN USA – 19 June 2018:​ Medibio Limited​ (MEB​ or the Company​)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring [...]

Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health Sydney, Australia, and Minneapolis, [...]

Are biometrics the new Superhero of mental health? By Peta Slocombe If there was a Hall of Fame, you’d probably find it has been 40 years since mental health had the closest thing to a Superhero. There, a little [...]

Sydney, Australia and Minneapolis, MN USA – 9 May 2018:​ ​Medibio Limited​ (​MEB​ or the Company​)(ASX: MEB)(OTCQB: MDBIF), ​a mental health technology company, today announced the execution of a commercial contract with St. John of God Health Care (SJGHC) [...]

"Michael Phelps, World Champion Athlete and Mental Health Advocate, Appointed to Medibio Board of Directors" Medibio was featured on the Nasdaq Big Screen at New York's Time Square today!

Medibio Limited Begins Trading on OTCQB Under Ticker Symbol MDBIF Sydney, Australia – 5 June 2017: Medibio Limited (ASX:MEB) (OTCQB: MDBIF) announced today that its common stock will begin trading on the OTC Market Group’s OTCQB® Venture Market [...]